In a more recent study conducted in 34 women with suspected breast cancer, a novel GRPR antagonist, 68Ga-NOTA-RM26, was able to delineate primary breast tumors in 29/34 patients and lymph nodes metastases in 15/18 patients with node-positive disease [6]. This evidence concerns the gene GRPR and breast cancer.